European regulators have given Agilent Technologies expanded CE mark approval for its Dako PD-L1 IHC 28-8 pharmDx test for use in determining which urothelial cancer patients are most likely to benefit from Bristol-Myers Squibb's cancer drug Opdivo. The test is already approved for use in tumor cell PD-L1 expression for melanoma, non-squamous non-small cell lung cancer and squamous cell carcinoma of the head and neck.
EU expands approval for Agilent's Opdivo companion Dx
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.